UA125393C2 - Модулятори соматостатину та їх застосування - Google Patents

Модулятори соматостатину та їх застосування Download PDF

Info

Publication number
UA125393C2
UA125393C2 UAA201901274A UAA201901274A UA125393C2 UA 125393 C2 UA125393 C2 UA 125393C2 UA A201901274 A UAA201901274 A UA A201901274A UA A201901274 A UAA201901274 A UA A201901274A UA 125393 C2 UA125393 C2 UA 125393C2
Authority
UA
Ukraine
Prior art keywords
quinolin
difluorophenyl
fluoro
aminopiperidin
methylphenyl
Prior art date
Application number
UAA201901274A
Other languages
English (en)
Ukrainian (uk)
Inventor
Цзян Жао
Сандон Хан
Сун Хіі Кім
Сун Хии Ким
Шимяо Ванг
Юнфей Жу
Original Assignee
Крінетікс Фармасьютікалс, Інк.
Кринетикс Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Крінетікс Фармасьютікалс, Інк., Кринетикс Фармасьютикалс, Инк. filed Critical Крінетікс Фармасьютікалс, Інк.
Publication of UA125393C2 publication Critical patent/UA125393C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
UAA201901274A 2016-07-14 2017-07-12 Модулятори соматостатину та їх застосування UA125393C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362493P 2016-07-14 2016-07-14
US201662411338P 2016-10-21 2016-10-21
PCT/US2017/041694 WO2018013676A1 (en) 2016-07-14 2017-07-12 Somatostatin modulators and uses thereof

Publications (1)

Publication Number Publication Date
UA125393C2 true UA125393C2 (uk) 2022-03-02

Family

ID=60941935

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201901274A UA125393C2 (uk) 2016-07-14 2017-07-12 Модулятори соматостатину та їх застосування

Country Status (24)

Country Link
US (6) US9896432B2 (cg-RX-API-DMAC7.html)
EP (2) EP3484865B1 (cg-RX-API-DMAC7.html)
JP (2) JP6967577B2 (cg-RX-API-DMAC7.html)
KR (2) KR102324042B1 (cg-RX-API-DMAC7.html)
CN (2) CN115557929A (cg-RX-API-DMAC7.html)
AU (2) AU2017296392B2 (cg-RX-API-DMAC7.html)
CA (1) CA3030423A1 (cg-RX-API-DMAC7.html)
DK (1) DK3484865T3 (cg-RX-API-DMAC7.html)
ES (1) ES2931472T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221279T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060182T2 (cg-RX-API-DMAC7.html)
IL (1) IL264178B2 (cg-RX-API-DMAC7.html)
LT (1) LT3484865T (cg-RX-API-DMAC7.html)
MX (1) MX390120B (cg-RX-API-DMAC7.html)
NZ (1) NZ750174A (cg-RX-API-DMAC7.html)
PL (1) PL3484865T3 (cg-RX-API-DMAC7.html)
PT (1) PT3484865T (cg-RX-API-DMAC7.html)
RS (1) RS63776B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201900349VA (cg-RX-API-DMAC7.html)
SM (1) SMT202200465T1 (cg-RX-API-DMAC7.html)
TW (1) TWI789355B (cg-RX-API-DMAC7.html)
UA (1) UA125393C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018013676A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201900317B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63776B1 (sr) * 2016-07-14 2022-12-30 Crinetics Pharmaceuticals Inc Modulatori somatostatina i njihove upotrebe
KR20190121404A (ko) * 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
RS63387B1 (sr) * 2018-01-17 2022-08-31 Crinetics Pharmaceuticals Inc Postupak proizvodnje modulatora somatostatina
JP7365347B2 (ja) * 2018-02-12 2023-10-19 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターおよびその使用
EP3807248A4 (en) * 2018-05-29 2021-10-27 Council of Scientific and Industrial Research BICYCLIC TOPOISOMERASE I INHIBITOR COMPOUNDS, THEIR PREPARATION AND USE
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
TWI841768B (zh) 2019-08-14 2024-05-11 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
MA66139B1 (fr) * 2020-09-09 2025-09-30 Crinetics Pharmaceuticals, Inc. Formulations d'un modulateur de somatostatine
US11773076B2 (en) 2021-02-17 2023-10-03 Crinetics Pharmaceuticals, Inc. Crystalline forms of a somatostatin modulator
WO2022251212A2 (en) * 2021-05-25 2022-12-01 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of disease
JP7784437B2 (ja) 2021-09-28 2025-12-11 デンカ株式会社 クロロプレン系ブロック共重合体、ラテックス、ラテックス組成物、及びゴム組成物
MX2024008598A (es) * 2022-01-11 2024-07-23 Crinetics Pharmaceuticals Inc Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide.
WO2023238112A1 (en) 2022-06-10 2023-12-14 Assia Chemical Industries Ltd. Solid state forms of paltusotine and process for preparation thereof
CR20250214A (es) * 2022-10-28 2025-08-22 Basecamp Bio Inc Agonistas del receptor 2 de somatostatina y sus usos
WO2024129614A1 (en) 2022-12-13 2024-06-20 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof
US12208092B2 (en) 2023-03-28 2025-01-28 Crinetics Pharmaceuticals, Inc. Compositions and methods for administering paltusotine to patients with hepatic impairment
WO2025111318A1 (en) * 2023-11-22 2025-05-30 Crinetics Pharmaceuticals, Inc. Somatostatin subtype receptor 3 (sstr3) agonists and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1035154A (en) 1910-05-16 1912-08-13 Ernest G Clark Machine for rectifying perforated music and masters.
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
AU2002352868A1 (en) 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
KR100659428B1 (ko) 2002-02-04 2006-12-19 에프. 호프만-라 로슈 아게 Ｎｐｙ 길항제로서의 퀴놀린 유도체
US7767817B2 (en) 2003-09-05 2010-08-03 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
WO2006017326A1 (en) * 2004-07-13 2006-02-16 Glaxo Group Limited Antibacterial agents
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
JP2009527562A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
AU2007223801A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US20090258853A1 (en) 2006-03-13 2009-10-15 Brian Eastman Somatostatin Agonists
AU2009289316A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
GB0818241D0 (en) * 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
MX342879B (es) * 2010-07-30 2016-10-14 Oncotherapy Science Inc * Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
EP2726465A1 (en) 2011-05-23 2014-05-07 Elan Pharmaceuticals Inc. Inhibitors of lrrk2 kinase activity
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CA2888485C (en) * 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
DK3053916T3 (en) 2013-09-30 2019-04-15 Ono Pharmaceutical Co RELATIONSHIP WITH SOMATOSTATIN RECEPTOR AGONIST ACTIVITY AND PHARMACEUTICAL USE THEREOF
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
EP3124487A1 (en) 2014-03-24 2017-02-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MX385424B (es) 2015-12-17 2025-03-18 Merck Patent Gmbh Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios.
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
RS63776B1 (sr) * 2016-07-14 2022-12-30 Crinetics Pharmaceuticals Inc Modulatori somatostatina i njihove upotrebe
RS63387B1 (sr) 2018-01-17 2022-08-31 Crinetics Pharmaceuticals Inc Postupak proizvodnje modulatora somatostatina
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3999509A4 (en) 2019-07-17 2023-07-19 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
MA66139B1 (fr) 2020-09-09 2025-09-30 Crinetics Pharmaceuticals, Inc. Formulations d'un modulateur de somatostatine

Also Published As

Publication number Publication date
SMT202200465T1 (it) 2023-01-13
JP6967577B2 (ja) 2021-11-17
SG11201900349VA (en) 2019-02-27
JP2022028675A (ja) 2022-02-16
BR112019000692A2 (pt) 2019-04-24
MX390120B (es) 2025-03-20
KR102324042B1 (ko) 2021-11-09
EP3484865B1 (en) 2022-09-14
CA3030423A1 (en) 2018-01-18
MX2019000588A (es) 2019-09-09
US20180016252A1 (en) 2018-01-18
RS63776B1 (sr) 2022-12-30
US20200190053A1 (en) 2020-06-18
IL264178B2 (en) 2024-05-01
US20190382367A1 (en) 2019-12-19
IL264178B1 (en) 2024-01-01
BR112019000692A8 (pt) 2022-03-03
HRP20221279T1 (hr) 2022-12-23
US20210171492A1 (en) 2021-06-10
ES2931472T3 (es) 2022-12-29
EP3484865A4 (en) 2019-12-25
US11414397B2 (en) 2022-08-16
WO2018013676A1 (en) 2018-01-18
US20220380337A1 (en) 2022-12-01
AU2020277122A1 (en) 2020-12-24
CN115557929A (zh) 2023-01-03
IL264178A (en) 2019-02-28
US9896432B2 (en) 2018-02-20
JP2019520415A (ja) 2019-07-18
LT3484865T (lt) 2022-11-10
NZ750174A (en) 2023-04-28
KR20190026914A (ko) 2019-03-13
DK3484865T3 (da) 2022-10-31
PT3484865T (pt) 2022-11-03
EP3484865A1 (en) 2019-05-22
HUE060182T2 (hu) 2023-02-28
US10875839B2 (en) 2020-12-29
US10597377B2 (en) 2020-03-24
PL3484865T3 (pl) 2023-01-09
CN109715612A (zh) 2019-05-03
US10351547B2 (en) 2019-07-16
CN109715612B (zh) 2022-09-16
EP4163276A1 (en) 2023-04-12
TW201805276A (zh) 2018-02-16
ZA201900317B (en) 2022-10-26
TWI789355B (zh) 2023-01-11
AU2017296392A1 (en) 2019-02-28
US20190002431A1 (en) 2019-01-03
AU2017296392B2 (en) 2020-09-24
KR20210134838A (ko) 2021-11-10

Similar Documents

Publication Publication Date Title
UA125393C2 (uk) Модулятори соматостатину та їх застосування
AU2016202949A1 (en) Novel nicotinamide derivative or salt thereof
EP3041841B1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EP3752498B1 (en) Somatostatin modulators and uses thereof
US20260008767A1 (en) Somatostatin modulators and uses thereof
EA040023B1 (ru) Модуляторы соматостатина и их применения
BR112019000692B1 (pt) Compostos moduladores de somatostatina, composição farmacêutica e uso do referido composto
HK40008169B (en) Somatostatin modulators and uses thereof
HK40008169A (en) Somatostatin modulators and uses thereof